About us

PRESCRIPTION MEDICINE

The global dermatology prescription market size is expected to continue growing at a rapid pace in the years to come, expected to reach USD 64 billion by 2027.
In our Prescription Medicine business, we provide dermatologists and other healthcare professionals with prescription treatments that offer patients relief from the burden of moderate to severe skin diseases. We have a wide-ranging portfolio and our innovation is focused on developing new therapies in more disease areas with unmet medical needs.
One of our key priorities is to advance the development of the investigational therapy Nemolizumab in patients with Atopic Dermatitis and Prurigo Nodularis for which we have initiated Phase 3 clinical studies.

 

OUR AESTHETIC SOLUTIONS

190403_Galderma_Portfolio_Gabriella_026_NoFX_RGB_Medium_580x268_0.jpg

OUR CONSUMER SOLUTIONS

consumer_care_header(580x268).jpg

OUR BRANDS

Galderma_Content Images_Our Brands_4.png